Key result
Despite being a highly cost-effective and standard treatment for cardiovascular disease, aspirin suffers from poor patient and physician compliance.
Answers are grounded in this paper and cite their sources.
Highlights the significant gap between the proven efficacy of aspirin in cardiovascular disease and actual patient compliance in clinical practice.
The first randomised controlled trial of aspirin in the prevention of vascular events was conducted in South Wales in 1974.1 Since then overviews of numerous trials2 3 have established aspirin, used in cardiovascular disease, as the most thoroughly tested and the most highly cost effective drug available in clinical practice. Aspirin is now a standard part of both the early and the long term management of coronary thrombosis. Unfortunately, there is evidence that within Wales only about half such patients are actually taking this drug.4 Other research has identified that poor compliance is not confined to Wales. A number of doctors taking part in the US Physicians Health Study admitted that they had taken aspirin on less than half the study days.
No takes yet. Share an insight, caveat, or question.
Woollard et al. (2008) conducted an editorial in Cardiovascular disease and coronary thrombosis. Aspirin was evaluated. Despite being a highly cost-effective and standard treatment for cardiovascular disease, aspirin suffers from poor patient and physician compliance.
Synapse has enriched 10 related papers. Consider them for comparative context: